Treatment of Primary Chronic Glomerulonephritis with Rehmannia Glutinosa Acteosides in Combination with the Angiotensin Receptor Blocker Irbesartan: A Randomized Controlled Trial

被引：38

作者：

Qiu, HongYu ^{[1
]}

Fu, Ping ^{[1
]}

Fan, WenXing ^{[1
]}

Zuo, Chuan ^{[1
]}

Feng, Ping ^{[2
]}

Shi, Peng ^{[3
]}

Cao, Lina ^{[4
]}

Liu, Fang ^{[1
]}

Zhou, Li ^{[1
]}

Chen, Feng ^{[1
]}

Zhong, Hui ^{[1
]}

Gou, ZhongPing ^{[2
]}

Liang, YaPing ^{[1
]}

Shi, Mei ^{[1
]}

机构：

[1] Sichuan Univ, Dept Nephrol, West China Hosp, Chengdu 610064, Sichuan, Peoples R China

[2] Sichuan Univ, Inst Clin Trials, West China Hosp, Chengdu 610064, Sichuan, Peoples R China

[3] Mil 451 Hosp, Nephrol Dept Tradit Chinese Med, Xian, Shanxi, Peoples R China

[4] Xian Yang Cent Hosp, Dept Nephrol, Xianyang, Shanxi, Peoples R China

来源：

PHYTOTHERAPY RESEARCH | 2014年 / 28卷 / 01期

关键词：

Rehmannia glutinosa acteosides; chronic disease; randomized clinical trials; Traditional Chinese Medicine; general acteoside in extract of Rehmanniae leaves; NEPHROPATHY; THERAPY; DISEASE;

D O I：

10.1002/ptr.4973

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis. A total of 479 patients diagnosed with primary chronic glomerulonephritis were recruited from outpatient clinics and were randomly assigned to the treatment group (Rehmannia glutinosa acteosides, two 200-mg capsules, bid; and irbesartan, one 150-mg tablet, qd) or the control group (irbesartan, one 150-mg tablet, qd). The primary outcome was 24-h urinary protein. Secondary outcome measures included blood pressure, estimated glomerular filtration rate, erythrocyturia, serum alanine aminotransferase, aspartate transaminase and electrolytes. After 8 weeks of treatment, the treatment group showed a mean reduction in 24-h proteinuria of 36.42% compared to baseline, which was significantly higher than the mean reduction from baseline of 27.97% in the control group (P=0.0278).Adverse drug reactions occurred at a similarly low rate in the treatment group (0.4%) and control group (1.2%, P=0.3724). In the treatment of chronic glomerulonephritis, the combination of Rehmannia glutinosa acteosides and irbesartan can reduce proteinuria more effectively than irbesartan alone. Copyright (c) 2013 John Wiley & Sons, Ltd.

引用

页码：132 / 136

页数：5

共 16 条

[1]

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials [J].